Announced
Synopsis
ADQ, a holding company, agreed to invest $75m in Biocon Biologics, a biopharmaceutical company, valuing the company at $4.17bn. “This investment is an endorsement of the value that the Biocon Biologics business has built as a fully integrated pure-play biosimilars company and will enable us to expand our capabilities further. We are committed to pursue our affordable innovation model to generate savings for the healthcare systems worldwide,” Kiran Mazumdar-Shaw, Biocon Executive Chairperson.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.